Endoglin-Aptamer-Functionalized Liposome-Equipped PD-1-Silenced T Cells Enhance Antitumoral Immunotherapeutic Effects

References

• Romero Y, Trapani D, Johnson S, et al. National cancer control plans: a global analysis. Lancet Oncol. 2018;19(10):e546–e555. doi:10.1016/S1470-2045(18)30681-8
   PubMed Web of Science ®Google Scholar
• Given LS, Hohman K, Kostelecky B, Vinson C. Cancer control planning: self-assessment for pre-planning, development, implementation and evaluation of national cancer control plans. Cancer Causes Control. 2018;29(12):1297–1303. doi:10.1007/s10552-018-1123-z
   PubMedGoogle Scholar
• Hirata E, Sahai E. Tumor Microenvironment and differential responses to therapy. Cold Spring Harb Perspect Med. 2017;7(7):a026781. doi:10.1101/cshperspect.a026781
   PubMed Web of Science ®Google Scholar
• Fane M, Weeraratna AT. How the ageing microenvironment influences tumour progression. Nat Rev Cancer. 2020;20(2):89–106. doi:10.1038/s41568-019-0222-9
   PubMed Web of Science ®Google Scholar
• Lee DA. Cellular therapy: adoptive immunotherapy with expanded natural killer cells. Immunol Rev. 2019;290(1):85–99. doi:10.1111/imr.12793
   PubMed Web of Science ®Google Scholar
• Waidmann O. Recent developments with immunotherapy for hepatocellular carcinoma. Expert Opin Biol Ther. 2018;18(8):905–910. doi:10.1080/14712598.2018.1499722
   PubMed Web of Science ®Google Scholar
• McHayleh W, Bedi P, Sehgal R, Solh M. Chimeric antigen receptor T-cells: the future is now. J Clin Med. 2019;8(2):207. doi:10.3390/jcm8020207
   PubMed Web of Science ®Google Scholar
• Roselli E, Frieling JS, Thorner K, Ramello MC, Lynch CC, Abate-Daga D. CAR-T engineering: optimizing signal transduction and effector mechanisms. BioDrugs. 2019;33(6):647–659. doi:10.1007/s40259-019-00384-z
   PubMedGoogle Scholar
• Jiang X, Xu J, Liu M, et al. Adoptive CD8(+) T cell therapy against cancer: challenges and opportunities. Cancer Lett. 2019;462:23–32. doi:10.1016/j.canlet.2019.07.017
   PubMedGoogle Scholar
• Zhang E, Gu J, Xu H. Prospects for chimeric antigen receptor-modified T cell therapy for solid tumors. Mol Cancer. 2018;17(1):7. doi:10.1186/s12943-018-0759-3
   PubMed Web of Science ®Google Scholar
• Adusumilli PS, Cherkassky L, Villena-Vargas J, et al. Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity. Sci Transl Med. 2014;6(261):261ra151. doi:10.1126/scitranslmed.3010162
   PubMed Web of Science ®Google Scholar
• Thistlethwaite FC, Gilham DE, Guest RD, et al. The clinical efficacy of first-generation carcinoembryonic antigen (CEACAM5)-specific CAR T cells is limited by poor persistence and transient pre-conditioning-dependent respiratory toxicity. Cancer Immunol Immunother. 2017;66(11):1425–1436. doi:10.1007/s00262-017-2034-7
   PubMed Web of Science ®Google Scholar
• Sasawatari S, Okamoto Y, Kumanogoh A, Toyofuku T. Blockade of N-glycosylation promotes antitumor immune response of t cells. J Immunol. 2020;204(5):1373–1385. doi:10.4049/jimmunol.1900937
   PubMedGoogle Scholar
• Shang N, Figini M, Shangguan J, et al. Dendritic cells based immunotherapy. Am J Cancer Res. 2017;7(10):2091–2102.
   PubMed Web of Science ®Google Scholar
• Pang YB, He J, Cui BY, et al. A potential antitumor effect of dendritic cells fused with cancer stem cells in hepatocellular carcinoma. Stem Cells Int. 2019;2019:5680327. doi:10.1155/2019/5680327
   PubMedGoogle Scholar
• Mayoux M, Roller A, Pulko V, et al. Dendritic cells dictate responses to PD-L1 blockade cancer immunotherapy. Sci Transl Med. 2020;12:(534):eaav7431. doi:10.1126/scitranslmed.aav7431
   Google Scholar
• Kajihara M, Takakura K, Ohkusa T, Koido S. The impact of dendritic cell-tumor fusion cells on cancer vaccines - past progress and future strategies. Immunotherapy. 2015;7(10):1111–1122. doi:10.2217/imt.15.73
   PubMedGoogle Scholar
• Koido S. Dendritic-tumor fusion cell-based cancer vaccines. Int J Mol Sci. 2016;17(6):828. doi:10.3390/ijms17060828
   PubMedGoogle Scholar
• He J, Zheng R, Zhang Z, et al. Collagen I enhances the efficiency and anti-tumor activity of dendritic-tumor fusion cells. Oncoimmunology. 2017;6(12):e1361094. doi:10.1080/2162402X.2017.1361094
   PubMed Web of Science ®Google Scholar
• Hegde PS, Chen DS. Top 10 Challenges in Cancer Immunotherapy. Immunity. 2020;52(1):17–35. doi:10.1016/j.immuni.2019.12.011
   PubMed Web of Science ®Google Scholar
• Xue S, Hu M, Iyer V, Yu J. Blocking the PD-1/PD-L1 pathway in glioma: a potential new treatment strategy. J Hematol Oncol. 2017;10(1):81. doi:10.1186/s13045-017-0455-6
   PubMed Web of Science ®Google Scholar
• Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 2018;359(6382):1350–1355. doi:10.1126/science.aar4060
   PubMed Web of Science ®Google Scholar
• He X, Xu C. Immune checkpoint signaling and cancer immunotherapy. Cell Res. 2020;30(8):660–669. doi:10.1038/s41422-020-0343-4
   PubMed Web of Science ®Google Scholar
• Brown CC, Wolchok JD. PD-L1 blockade therapy: location, location, location. Cancer Cell. 2020;38(5):615–617. doi:10.1016/j.ccell.2020.10.017
   PubMedGoogle Scholar
• Knauss S, Preusse C, Allenbach Y, et al. PD1 pathway in immune-mediated myopathies: pathogenesis of dysfunctional T cells revisited. Neurol Neuroimmunol Neuroinflamm. 2019;6(3):e558. doi:10.1212/NXI.0000000000000558
   PubMedGoogle Scholar
• Bardhan K, Anagnostou T, Boussiotis VA. The PD1: PD-L1/2 pathway from discovery to clinical implementation. Front Immunol. 2016;7:550. doi:10.3389/fimmu.2016.00550
   PubMed Web of Science ®Google Scholar
• Chinai JM, Janakiram M, Chen F, Chen W, Kaplan M, Zang X. New immunotherapies targeting the PD-1 pathway. Trends Pharmacol Sci. 2015;36(9):587–595. doi:10.1016/j.tips.2015.06.005
   PubMed Web of Science ®Google Scholar
• Hu W, Zi Z, Jin Y, et al. CRISPR/Cas9-mediated PD-1 disruption enhances human mesothelin-targeted CAR T cell effector functions. Cancer Immunol Immunother. 2019;68(3):365–377. doi:10.1007/s00262-018-2281-2
   PubMed Web of Science ®Google Scholar
• Rupp LJ, Schumann K, Roybal KT, et al. CRISPR/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells. Sci Rep. 2017;7(1):737. doi:10.1038/s41598-017-00462-8
   PubMed Web of Science ®Google Scholar
• Nimjee SM, White RR, Becker RC, Sullenger BA. Aptamers as therapeutics. Annu Rev Pharmacol Toxicol. 2017;57:61–79. doi:10.1146/annurev-pharmtox-010716-104558
   PubMed Web of Science ®Google Scholar
• Kaur H, Bruno JG, Kumar A, Sharma TK. Aptamers in the therapeutics and diagnostics pipelines. Theranostics. 2018;8(15):4016–4032. doi:10.7150/thno.25958
   PubMed Web of Science ®Google Scholar
• Tang Y, Liu H, Chen H, et al. Advances in aptamer screening and drug delivery. J Biomed Nanotechnol. 2020;16(6):763–788. doi:10.1166/jbn.2020.2943
   PubMedGoogle Scholar
• Czechowska K, Lannigan J, Wang L, et al. Cyt-Geist: current and future challenges in cytometry: reports of the CYTO 2018 conference workshops. Cytometry A. 2019;95(6):598–644. doi:10.1002/cyto.a.23777
   PubMedGoogle Scholar
• He Y, Wang M, Fu M, et al. Iron(II) phthalocyanine loaded and AS1411 aptamer targeting nanoparticles: a nanocomplex for dual modal imaging and photothermal therapy of breast cancer. Int J Nanomedicine. 2020;15:5927–5949. doi:10.2147/IJN.S254108
   PubMed Web of Science ®Google Scholar
• Hanafi-Bojd MY, Moosavian Kalat SA, Taghdisi SM, Ansari L, Abnous K, Malaekeh-Nikouei B. MUC1 aptamer-conjugated mesoporous silica nanoparticles effectively target breast cancer cells. Drug Dev Ind Pharm. 2018;44(1):13–18. doi:10.1080/03639045.2017.1371734
   PubMed Web of Science ®Google Scholar
• Zeng YB, Yu ZC, He YN, et al. Salinomycin-loaded lipid-polymer nanoparticles with anti-CD20 aptamers selectively suppress human CD20+ melanoma stem cells. Acta Pharmacol Sin. 2018;39(2):261–274. doi:10.1038/aps.2017.166
   PubMedGoogle Scholar
• Dou XQ, Wang H, Zhang J, et al. Aptamer-drug conjugate: targeted delivery of doxorubicin in a HER3 aptamer-functionalized liposomal delivery system reduces cardiotoxicity. Int J Nanomedicine. 2018;13:763–776. doi:10.2147/IJN.S149887
   PubMed Web of Science ®Google Scholar
• Chen W, Dong W, Wang J, Wen Z, Hao X. Elevated expressions of survivin and endoglin in patients with hepatic carcinoma. Cancer Biother Radiopharm. 2019;34(1):7–12. doi:10.1089/cbr.2018.2539
   PubMed Web of Science ®Google Scholar
• Kasprzak A, Adamek A. Role of endoglin (CD105) in the progression of hepatocellular carcinoma and anti-angiogenic therapy. Int J Mol Sci. 2018;19:12. doi:10.3390/ijms19123887
   Google Scholar
• Qian L, Tang Z, Yin S, et al. Fusion of dendritic cells and cancer-associated fibroblasts for activation of anti-tumor cytotoxic t lymphocytes. J Biomed Nanotechnol. 2018;14(10):1826–1835. doi:10.1166/jbn.2018.2616
   PubMed Web of Science ®Google Scholar
• Tang Z, Mo F, Liu A, et al. A nanobody against cytotoxic T-lymphocyte associated antigen-4 increases the anti-tumor effects of specific CD8(+) T cells. J Biomed Nanotechnol. 2019;15(11):2229–2239. doi:10.1166/jbn.2019.2859
   PubMedGoogle Scholar
• Schelté P, Boeckler C, Frisch B, Schuber F. Differential reactivity of maleimide and bromoacetyl functions with thiols: application to the preparation of liposomal diepitope constructs. Bioconjug Chem. 2000;11(1):118–123. doi:10.1021/bc990122k
   PubMedGoogle Scholar
• Yang X, Zhao J, Duan S, et al. Enhanced cytotoxic T lymphocytes recruitment targeting tumor vasculatures by endoglin aptamer and IP-10 plasmid presenting liposome-based nanocarriers. Theranostics. 2019;9(14):4066–4083. doi:10.7150/thno.33383
   PubMed Web of Science ®Google Scholar
• Tian H, Huang JJ, Golzio C, et al. Endoglin interacts with VEGFR2 to promote angiogenesis. FASEB j. 2018;32(6):2934–2949. doi:10.1096/fj.201700867RR
   PubMed Web of Science ®Google Scholar
• Redeker A, Arens R. Improving adoptive T cell therapy: the particular role of t cell costimulation, cytokines, and post-transfer vaccination. Front Immunol. 2016;7:345. doi:10.3389/fimmu.2016.00345
   PubMed Web of Science ®Google Scholar
• Zappasodi R, Merghoub T, Wolchok JD. Emerging concepts for immune checkpoint blockade-based combination therapies. Cancer Cell. 2018;33(4):581–598. doi:10.1016/j.ccell.2018.03.005
   PubMed Web of Science ®Google Scholar
• Friedman CF, Proverbs-Singh TA, Postow MA. Treatment of the immune-related adverse effects of immune checkpoint inhibitors: a review. JAMA Oncol. 2016;2(10):1346–1353. doi:10.1001/jamaoncol.2016.1051
   PubMed Web of Science ®Google Scholar
• Rotte A, Jin JY, Lemaire V. Mechanistic overview of immune checkpoints to support the rational design of their combinations in cancer immunotherapy. Ann Oncol. 2018;29(1):71–83. doi:10.1093/annonc/mdx686
   PubMed Web of Science ®Google Scholar
• Poggio M, Hu T, Pai CC, et al. Suppression of exosomal PD-L1 induces systemic anti-tumor immunity and memory. Cell. 2019;177(2):414–427.e413. doi:10.1016/j.cell.2019.02.016
   PubMed Web of Science ®Google Scholar
• Wu Y, Chen W, Xu ZP, Gu W. PD-L1 Distribution and perspective for cancer immunotherapy-blockade, knockdown, or inhibition. Front Immunol. 2019;10:2022. doi:10.3389/fimmu.2019.02022
   PubMed Web of Science ®Google Scholar
• Schumann K, Lin S, Boyer E, et al. Generation of knock-in primary human T cells using Cas9 ribonucleoproteins. Proc Natl Acad Sci U S A. 2015;112(33):10437–10442. doi:10.1073/pnas.1512503112
   PubMed Web of Science ®Google Scholar
• Li L, Hu S, Chen X. Non-viral delivery systems for CRISPR/Cas9-based genome editing: challenges and opportunities. Biomaterials. 2018;171:207–218. doi:10.1016/j.biomaterials.2018.04.031
   PubMed Web of Science ®Google Scholar
• Wei J, Luo C, Wang Y, et al. PD-1 silencing impairs the anti-tumor function of chimeric antigen receptor modified T cells by inhibiting proliferation activity. J Immunother Cancer. 2019;7(1):209. doi:10.1186/s40425-019-0685-y
   PubMed Web of Science ®Google Scholar
• Tan C, Dannull J, Nair SK, et al. Local secretion of IL-12 augments the therapeutic impact of dendritic cell-tumor cell fusion vaccination. J Surg Res. 2013;185(2):904–911. doi:10.1016/j.jss.2013.06.045
   PubMedGoogle Scholar
• Wang Y, Xiang Y, Xin VW, et al. Dendritic cell biology and its role in tumor immunotherapy. J Hematol Oncol. 2020;13(1):107. doi:10.1186/s13045-020-00939-6
   PubMed Web of Science ®Google Scholar
• Olusanya TOB, Haj Ahmad RR, Ibegbu DM, Smith JR, Elkordy AA. Liposomal drug delivery systems and anticancer drugs. Molecules. 2018;23(4):907. doi:10.3390/molecules23040907
   PubMed Web of Science ®Google Scholar
• Maeki M, Kimura N, Sato Y, Harashima H, Tokeshi M. Advances in microfluidics for lipid nanoparticles and extracellular vesicles and applications in drug delivery systems. Adv Drug Deliv Rev. 2018;128:84–100. doi:10.1016/j.addr.2018.03.008
   PubMed Web of Science ®Google Scholar
• Gudbergsson JM, Jønsson K, Simonsen JB, Johnsen KB. Systematic review of targeted extracellular vesicles for drug delivery - Considerations on methodological and biological heterogeneity. J Control Release. 2019;306:108–120. doi:10.1016/j.jconrel.2019.06.006
   PubMed Web of Science ®Google Scholar
• Hori SI, Herrera A, Rossi JJ, Zhou J. Current advances in aptamers for cancer diagnosis and therapy. Cancers(Basel). 2018;10(1):9. doi:10.3390/cancers10010009
   PubMed Web of Science ®Google Scholar
• Delcanale P, Porciani D, Pujals S, et al. Aptamers with tunable affinity enable single-molecule tracking and localization of membrane receptors on living cancer cells. Angew Chem Int Ed Engl. 2020;59(42):18546–18555. doi:10.1002/anie.202004764
   PubMedGoogle Scholar
• Rossi E, Sanz-Rodriguez F, Eleno N, et al. Endothelial endoglin is involved in inflammation: role in leukocyte adhesion and transmigration. Blood. 2013;121(2):403–415. doi:10.1182/blood-2012-06-435347
   PubMedGoogle Scholar
• Gallardo-Vara E, Tual-Chalot S, Botella LM, Arthur HM, Bernabeu C. Soluble endoglin regulates expression of angiogenesis-related proteins and induction of arteriovenous malformations in a mouse model of hereditary hemorrhagic telangiectasia. Dis Model Mech. 2018;11(9):dmm034397. doi:10.1242/dmm.034397
   PubMedGoogle Scholar
• Agrawal M, Ajazuddin Tripathi DK, et al. Recent advancements in liposomes targeting strategies to cross blood-brain barrier (BBB) for the treatment of Alzheimer’s disease. J Control Release. 2017;260:61–77. doi:10.1016/j.jconrel.2017.05.019
   PubMed Web of Science ®Google Scholar
• Xie G, Ivica NA, Jia B, et al. CAR-T cells targeting a nucleophosmin neoepitope exhibit potent specific activity in mouse models of acute myeloid leukaemia. Nat Biomed Eng. 2021;5(5):399–413. doi:10.1038/s41551-020-00625-5
   PubMed Web of Science ®Google Scholar
• Norelli M, Camisa B, Barbiera G, et al. Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells. Nat Med. 2018;24(6):739–748. doi:10.1038/s41591-018-0036-4
   PubMed Web of Science ®Google Scholar
• Giavridis T, van der Stegen SJC, Eyquem J, Hamieh M, Piersigilli A, Sadelain M. CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade. Nat Med. 2018;24(6):731–738. doi:10.1038/s41591-018-0041-7
   PubMed Web of Science ®Google Scholar